Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.40), $0.10 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $66 million versus the consensus estimate of $47.51 million.

“Our explosive growth in the first quarter was driven by strong domestic demand for the t:slim X2 insulin pump,” said John Sheridan, president and chief executive officer. “We believe the high interest in our Basal-IQ technology, our expanding international sales efforts and our robust product pipeline will continue to drive the Company’s positive momentum in 2019.”

“Our top priority for continued growth is to establish our position as a leader in innovation while maintaining the highest levels of quality throughout our business,” said Kim Blickenstaff, executive chairman. “This incredible start to the year, combined with our scalability initiatives, gives us even greater confidence in our ability to execute both our 2019 goals and the longer-term strategies of the Company.”

GUIDANCE:

Tandem Diabetes sees FY2019 revenue of $300-315 million, versus the consensus of $266.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.